The coronavirus vaccine developed by the Pfizer and BioNTech laboratories is “effective” against the Omicron variant after “three doses,” BioNTech said in a statement this Wednesday, December 8, that it wishes to prepare a vaccine more adapted to this alteration of the virus towards March.
According to studies carried out by laboratories, “the vaccine is still effective against the coronavirus, including the Omicron variant if three doses have been administered”, but “it is probably not sufficiently neutralized (the new variant) after two doses.”
“We are going to develop a specific vaccine against the Omicron variant and we hope to have it available by March,” they added.
“A third dose provides a level of antibodies to neutralize Omicron similar to that achieved after two doses” versus other variants, they explained.
According to Albert Bourla, president and CEO of Pfizer, quoted in the statement, two doses offer protection against Omicron and prevent developing the disease in a serious way, but after the studies carried out it is clear that the protection “improves” with a third dose .
Ómicron, considered “highly communicable” by the World Health Organization, was first detected in late November in South Africa and was quickly identified in several countries, causing a wave of panic, especially in Europe, where infections are multiplying .
